CrystalGenomics Collaborates with Paminogen for AI-Driven New Drug Discovery
Joo Joong-myung, CEO of CrystalGenomics (left), and Kim Young-hoon, CEO of Paminogen, are posing for a commemorative photo at the signing ceremony of a strategic partnership for AI-based innovative drug development. (Photo by CrystalGenomics)
View original image[Asia Economy Reporter Lee Chun-hee] CrystalGenomics recently announced on the 28th that it has formed a joint development partnership to discover new drug candidates using PaminoGen's artificial intelligence (AI) drug development platform 'LucyNet' at its headquarters in Pangyo, Seongnam-si, Gyeonggi Province.
Through this contract, the two companies plan to establish a collaborative relationship to discover new drug candidates for various indications such as Alzheimer's dementia, anticancer drugs, pain treatments, and anti-inflammatory drugs using their respective platform technologies, and to promote product development involving the discovery and technology transfer of new drug candidates.
CrystalGenomics will leverage its strengths in small molecule drug development to optimize lead compounds through its drug discovery platform technology, discover new drug candidates, and conduct animal efficacy experiments, drug evaluation, formulation research, and clinical trial development. PaminoGen will utilize LucyNet to discover new drug candidates.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Kim Young-hoon, CEO of PaminoGen, stated, “By adopting CrystalGenomics' AI platform LucyNet, we will be able to reduce the time and cost required to discover new drug candidates for various indications, thereby maximizing the efficiency of new drug development.” A CrystalGenomics representative also said, “To shorten the enormous costs and time involved in new drug development, we have formed a strategic alliance by combining CrystalGenomics' technological capabilities with PaminoGen's AI technology. Through this, we will actively pursue the discovery of new drug candidates for various indications.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
